secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001785530-22-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q2 net loss $14.6M; FDA clears IND for WTX-124; $145.7M cash runway through Q4 2023
--------------------------------------------------------------------------------

- Net loss of $14.6M in Q2 2022, vs $10.9M in Q2 2021; R&D expenses rose to $13.9M.
- FDA cleared IND for WTX-124 (IL-2 INDUKINE) for advanced solid tumors; Phase 1/1b trial to start.
- IND application for WTX-330 (IL-12 INDUKINE) planned in 2H22.
- Cash and equivalents $145.7M as of June 30, 2022, vs $157.5M at Dec 31, 2021.
- Collaboration revenue from Jazz deal $4.1M in Q2; Jazz upfront payment $15M, potential milestones up to $1.26B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/0001785530-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/howl-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001785530-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer